Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 283
Neurological, Psychiatric, and Developmental Disorders: Meeting the Challenge in the Developing World 9 Depression DEFINITION The term “depression” can apply to a transient mood, a sustained change in mood, a symptom, or a disorder. In this chapter, the term is used to refer to unipolar/major depression that is characterized by persistent low mood or sadness and accompanied by both physical and psychological symptoms of at least 2 weeks duration and with associated impact on social functioning. Both genetic and environmental factors are implicated in the etiology of depression.[1,2 and 3] Depression can present as acute episodes with depressive psychosis that are severely disabling yet often treatable, and when recurrent are controllable with maintenance pharmacotherapy. More often depression presents as an overlapping syndrome of depression, anxiety, and somatization forms such as bodily aches and pain, persistent backache, or genitourinary complaints. The diagnosis of a depressive illness is based on symptomatology, the severity and duration of the symptoms, and their impact on social functioning. Cases may be identified by means of self-rating on a questionnaire or observer assessment. In the latter case, the patient is interviewed by a health professional with training in assessment and diagnosis (the level of training being consistent with the local resources available for mental health services). The use of operational criteria strengthens the reliability of a conventional clinical interview. Operational diagnosis of psychiatric disorders, which seeks to identify patterns of symptoms that characterize a given illness most reliably, has been one of the major advances in psychiatry within the last 40 years. This diagnostic method allows clinicians to classify illnesses even when etiology is unknown, and hence to communicate about and conduct research on patients with similar characteristics.[4,5 and 6]
OCR for page 284
Neurological, Psychiatric, and Developmental Disorders: Meeting the Challenge in the Developing World While criteria for diagnosis have been standardized by the American Psychiatric Association  and the International Classification of Disease, 10th revision, their criteria are often of limited applicability in non-psychiatric settings, especially by primary care physicians, who often see patients with significant physical comorbidity. The accurate and timely diagnosis of depression is also complicated by the reluctance of patients to seek help because of the stigma associated with mental illness and by the nature of the complaints, which may often be thought to have a physical origin. There have been continuing studies on the reliability and validity of various methods of assessing depression, and in parallel there has been continuing work on evolving the classification systems and criteria used for these disorders. Current standardized classification systems used for depression appear in Table 9-1 and Table 9-2. TABLE 9-1 DSM-IV Criteria for Major Depressive Episode Five (or more) of the following symptoms have been present during the same 2-week period and represent a change from previous functioning: at least one of the symptoms is either (1) depressed mood or (2) loss of interest or pleasure. Depressed mood most of the day, nearly every day, as indicated by either subjective report or observation made by others; Markedly diminished interest or pleasure in all, or almost all, activities most of the day, nearly every day; Significant weight loss when not dieting or weight gain, or decrease or increase in appetite nearly every day; Insomnia or hypersomnia nearly every day; Psychomotor agitation or retardation nearly every day; Fatigue or loss of energy nearly every day; Feelings of worthlessness or excessive or inappropriate guilt nearly every day; Diminished ability to think or concentrate, or indecisiveness, nearly every day; Recurrent thoughts of death, recurrent suicidal ideation without a specific plan, or a suicide attempt or a specific plan for committing suicide. The symptoms do not meet criteria for a Mixed Episode (see Table F). The symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning. The symptoms are not due to the direct physiological effects of a substance or a general medical condition. The symptoms are not better accounted for by bereavement, i.e., after the loss of a loved one, the symptoms persist for longer than 2 months or are characterized by marked functional impairment, morbid preoccupation with worthlessness, suicidal ideation, psychotic symptoms, or psychomotor retardation. Source: 
OCR for page 285
Neurological, Psychiatric, and Developmental Disorders: Meeting the Challenge in the Developing World TABLE 9-2 ICD–10 Criteria for depressive episode General Episode must have lasted at least two weeks with symptoms nearly every day Change from normal functioning Key symptoms (n = 3) Depressed mood Anhedonia Fatigue/loss of energy Ancillary symptoms Weight and appetite change Sleep disturbance Subjective or objective agitation/retardation Low self esteem/confidence Self reproach/guilt Impaired thinking/concentration Suicidal thoughts Criteria Mild episode: 2 key, 4 symptoms in total Moderate episode: 2 key, 6 symptoms in total Severe episode: 3 key, 8 symptoms in total Exclusions No history ever of manic symptoms Not substance related Not organic Source:  The vast majority of research on the clinical features of depression has been conducted in the United States and Europe. Although far fewer in number, comparable studies from the developing world deserve careful attention, for they reveal significant differences in the presentation of depression among cultures, as well as core features common to all societies. Where possible in this chapter, we examine and compare findings from research in both developed and developing countries. For the purposes of comprehensive reporting, developed-country data are noted and used alone when findings from developing countries are not available. Although symptoms of depression are found everywhere, the Western bio-medical definition of depressive illness does not fit local concepts of illness in many developing communities.[10,11] Diagnoses of some mental disorders, including depression, have no conceptual equivalent in many languages. In non-European cultures, for example, use of the term “depression” often leads to the mistaken belief that sadness is an essential presenting feature of the disorder. While the experience of dysphoric mood may be universal, the concept of depressive disorder that focuses on mood must be recognized as having evolved within Western cultures, and therefore may not be universally applicable.
OCR for page 286
Neurological, Psychiatric, and Developmental Disorders: Meeting the Challenge in the Developing World Several authors also imply that Cartesian mind–body dichotomies are absent from certain cultural worldviews. Nichter (1982), for example, noted that South Havik Brahmin women express distressed emotions and other social problems in terms of dietary preference for certain foods, religious metaphors, or humoral imbalance in the body. Chinese popular explanations of mental illness ascribe problems to an imbalance in the psychosocial, physiological, or supernatural environment.[14,15] In African societies, health is viewed as more social than biological, and a unitary concept of psychosomatic interrelationship exists, with an apparent reciprocity between mind and matter. Because these conceptualizations strongly influence how people express the experience of psychological distress and dysphoric mood, standardized instruments may not be applied accurately without regard to cultural differences among populations. Nevertheless, studies show that depression is found in countries around the world with significantly different cultural traditions and levels of economic development.[17,18 and 19] The majority of people with depression eventually consult primary care doctors or nurses. While the overall symptoms of depression are ubiquitous in population surveys, research has shown somatic symptoms to be the most common presenting features of depression in developed as well as developing societies.[20,21 and 22] Most commonly, patients present with physical symptoms such as lack of energy or vitality, fatigue, and aches and pains.[20,23,24 and 25] Several studies in developing countries indicate that when people with depression present with somatic symptoms, they will upon questioning also report that they have experienced classic psychological symptoms of depression.[20,26,27] SCOPE OF THE PROBLEM Depressive disorders are common around the world and are associated with significant disability.[18,28,29,30 and 31] Depression is a long-term illness that produces significant psychological, physical, and functional disability.[28,32,33 and 34]. In a study conducted in Malaysia, over half the patients with chronic depression had dysfunctional behavior and experienced significant disabilities. Indeed, depression is estimated to be the leading cause of disability worldwide, accounting for more than 1 in 10 years of life lived with disability. Those suffering from depressive disorders also have high premature mortality, both from suicide and from physical illness.[ 17,18,35,36] Prevalence rates for depression vary among and between countries, but age of onset, social and environmental risk factors, and the preponderance of depressive disorders within families are similar across many cultures. Once recognized, depression can often be treated effectively. Though treatments are often not entirely curative, they offer significant relief from many of the debilitating symptoms of depression and can significantly improve the level of social functioning. Yet depressive disorders still remain largely underdiag-
OCR for page 287
Neurological, Psychiatric, and Developmental Disorders: Meeting the Challenge in the Developing World nosed and untreated around the world. Even in developed nations, depressed patients consistently receive either no medication or dosages that are ineffective in treating their symptoms.[19,37,38] Mortality Suicide Suicide is estimated to be the 10th leading cause of death worldwide. These estimates are based on nationally collected official data on suicide, which are thought to be significantly underestimated because of the stigma often associated with suicide. Reported rates of suicide vary widely throughout the world, with some of the highest rates being found in developing countries. For example, Sri Lanka  has the highest suicide rate in the world, followed closely by China. Factors affecting the suicide rate among a given population include the rate of depression; the prevalence of alcohol abuse; the presence of high-risk occupational and demographic groups, including people with severe mental illness; the availability of easy means of suicide; the degree of social integration; and cultural attitudes toward suicide. Psychological autopsy studies (which gather detailed information about the deceased from multiple key informants) indicate that more than 90 percent of people who commit suicide suffer from depression, substance abuse, psychosis, or some other form of mental illness.[ 41,42 and 43] In a major review of all studies of suicide reported in the English literature, Harris and Barraclough (1998) found that people with affective disorders combined (major depression, bipolar disorder, and affective disorder not otherwise specified) were 20 times more likely to kill themselves than the general population. In non-Western countries, however, completed suicides may be less likely to have received a psychiatric diagnosis because of the paucity of mental health services. Suicides often appear to be precipitated by a “last-straw phenomenon”: a recent social stress or life event in the context of multiple preexisting social stresses and an underlying mental illness. Official statistics tend to highlight the existence of social stresses rather than any underlying depression or other mental disorder. In settings where police officers, coroners, or physicians without mental health training are recording data about the principal causes of suicide, they are likely to focus on social and situational problems, rather than on preexisting depression. However, community surveys reveal that social problems are correlated with high rates of depression and anxiety.[45,46 and 47] Individuals with limited or dysfunctional social networks have been shown to be predisposed to depression, suicidal thoughts, and suicide.[ 48] Similarly, at the broader societal level, social disruption in contemporary industrialized society is believed to contribute to anomie, depression, and suicide. The suicide rate in Sri Lanka rose from 6.5 per 100,000 in 1950 to 47 per 100,000 in 1991 following
OCR for page 288
Neurological, Psychiatric, and Developmental Disorders: Meeting the Challenge in the Developing World a period of profound social upheaval and violence. War and social disruption have been associated with dramatically different suicide rates in various settings. Access to means of suicide has a major influence on the suicide rate.[ 50] Where rapid and effective means of self-destruction are readily available, people making impulsive gestures may commit suicide inadvertently. This may explain at least in part the extremely high rates of self-poisoning with insecticides among young women in China, Sri Lanka, and Western Samoa.[39,40,51,52] Medicines that can be obtained without prescription and are lethal in overdose may also be used for self-poisoning. Barbiturates are frequently used in this way in Nigeria, as are chloroquine in East Africa  and paracetamol in Europe. In addition, potentially lethal features of urban or rural landscapes appeal to those at risk by virtue of their symbolic association as an effective means of suicide. For example, tall buildings in Singapore and Hong Kong are popular sites for suicidal jumpers. Physical Illness A growing body of evidence links untreated depression to severe and life-threatening physical illness. Depression is associated with high premature mortality from physical causes, irrespective of premature mortality from suicide and trauma.[ 57,58 and 59] In a 40-year study, Ford and colleagues (1998) found that increased risk of coronary heart disease among people with major depression persisted for years after their first depressive episode. The increased risk was present even for myocardial infarctions occurring 10 years after the first depressive episode. Examining data from the Baltimore, Maryland, site of the Epidemiological Catchment Area Study, Pratt and co-workers (1996) found a fivefold increase in the risk of myocardial infarction following major depression and a twofold increase in those who suffered from less severe (subsyndromal) depression. The increased risk of cardiovascular disease with depression appears to apply equally to men and women.[60,61 and 62] Conversely, high rates of depression have been found in older patients suffering from cerebrovascular disease.[63,64] The significant disability often associated with recovering stroke patients may account for episodes of depression.[63,65] A recent study has suggested that cerebrovascular disease may have an etiopathological role in late-life depression. The increased damage to frontal and subcortical brain circuitry following stroke, transient ischemia, and hypertension may explain the high prevalence of depression in older individuals with vascular risk factors. Hormonal changes may go a long way toward explaining how depression results in physiological harm. For example, major depression leads to increased activation of the hypothalamic-pituitary-adrenal axis, which has in turn been associated with decreases in bone mineral density and increases in intra-
OCR for page 289
Neurological, Psychiatric, and Developmental Disorders: Meeting the Challenge in the Developing World abdominal fat, a known risk factor for coronary artery disease.[ 67,68 and 69] Researchers have examined the link between depression and osteoporosis.[ 70,71] One such study reported that depression-associated loss of bone density could be expected to increase hip fractures by more than 40 percent in 10 years. Social and Economic Costs The most comprehensive analysis to date of the worldwide impact of depression was performed in 1990 as part of the Global Burden of Disease (GBD) study. A major finding of this study, released in 1996, was that conditions such as mental disorders that disable, may cause less mortality than a number of physical conditions, but exact a high cost in disability throughout the world. Previous public health assessments, derived only from mortality data, did not rank mental disorders among the most burdensome diseases. Once disability was entered into the equation, mental disorders joined the ranks of cardiovascular and respiratory diseases, revealing a burden that surpassed both AIDS and all combined malignancies. The disability-adjusted life years (DALYs) methodology employed in the GBD (see Appendix B) provides a way of linking information on disease occurrence to information on short- and long-term outcomes, including disabilities and restrictions on participation in usual life situations. The disability component is weighted according to the severity of the disability. For example, in the original GBD study, disability caused by major depression was weighted as being equivalent to blindness or paraplegia. Thus calculated, the GBD study ranked depressive disorders (considered as a single diagnostic category) as the leading cause of disability worldwide. The GBD study also resulted in the prediction that in 2020, as the result of a combination of several demographic and epidemiological trends, unipolar major depression will rank second only to ischemic heart disease as the leading cause of disease and injury worldwide. These trends include the breakdown of extended family networks; increasing urbanization, migration, and mobility; and alcohol and drug abuse. In addition, the expected growth of the world's population, overall increases in life expectancy, and relative decreases in other communicable disorders are likely to result in depressive disorders becoming the leading cause of disability and overall disease burden worldwide. Continuing debate and further scientific studies will be required to confirm and refine the findings of the GBD study. However, it is important to note several limitations of the study: The figures used to calculate the burden due to depressive disorders are very low compared with the recent findings from large-scale epidemiological studies, such as the (U.S.) National Comorbidity Survey  and the British national psychiatric morbidity survey.
OCR for page 290
Neurological, Psychiatric, and Developmental Disorders: Meeting the Challenge in the Developing World The GBD study considered unipolar depression to be an episodic illness, while current concepts of the disorder describe it as a chronic relapsing medical illness. Likewise, the study considered depression only as an adult disease, yet overwhelming evidence suggests that depression also occurs with considerable frequency in childhood and adolescence. Only two disability weights were used to calculate the global burden of depressive disorders—one for treated cases, the other for untreated cases. The impact of comorbidity of depression with other mental and substance abuse disorders was not addressed. The burden on families, which is particularly significant for depression, was also not addressed. Given all of the above limitations, it is clear that the GBD estimates of the global burden of disability caused by depression are conservative at best, and more likely significantly underreport the worldwide burden exacted by depressive illness. Thus there is a pressing need for more precise information on the prevalence of and disability associated with these disorders in low-income countries. As noted above, the burden on family members of patients was not included in the GBD. However, the findings of several studies in both developed and developing countries reveal the significant toll exacted by depressive illness on family members and family stability.[ 76,77 and 78] Family members of depressed individuals may have increased rates of physical illness and frequent symptoms of fatigue.[79,80]. As described in Chapter 2, the stigma associated with mental illness is often great in both developed and developing countries. The burden of stigma is experienced not only by those who suffer from the illness, but also by their family members. This burden can lead to lost social and employment opportunities, social isolation, and unwillingness to assist the ill family member in seeking treatment. A few studies in developed countries have begun to examine the cost to the workforce caused by depression. Findings indicate that depressive illness has resulted in more days of disability and lost work time than chronic physical conditions such as heart disease, hypertension, and lower back pain.[82,83] The governments and employers of developing countries would be likely to see similar results. Studies to determine this economic burden may reinforce the argument for robust, proactive efforts on the part of governments and communities to prevent and treat depression. Recommendation 9-1. Depressive disorders exhibit high incidence and prevalence in the developing world, lead to disability and mortality, and exact high social costs. Therefore, they should be given high national priority as a public health problem of relevance to all government ministries, and be accorded high local priority by district planning committees.
OCR for page 291
Neurological, Psychiatric, and Developmental Disorders: Meeting the Challenge in the Developing World PREVALENCE AND INCIDENCE Over the last four decades, community surveys of mental disorders have provided diagnostic information, based on standardized methods of assessment, that permits comparison of research from different locations. Here we summarize selected epidemiological studies on depression conducted at the community level (Table 9-3) and on common mental disorders (which include depression) conducted at both the community (Table 9-4) and primary care (Table 9-5) levels. The accumulated evidence from these studies reveals the widespread prevalence of depression within both the developing and developed worlds, ranging from 8–43 percent. The variation in rates reported by these studies also appears to be due in part to cultural and environmental differences among the populations studied. Overall rates are higher in surveys of primary care attenders than in surveys of community populations. Precise case rates vary among locations and populations, and depend partly on the methodology used.[17,83] Differing rates of depression among population groups are discussed in greater detail in the subsequent discussion of risk factors. The most common psychiatric syndrome seen in community studies is a combination of depression and anxiety. For example, about one-half of those with a primary diagnosis of DSM-IV major depression also have an anxiety disorder.[84,85] This condition is sometimes referred to as comorbidity, but such a definition appears to be an artifact of classification systems designed primarily for hospital patients, rather than for the general population. When examined at the more universal level of primary care, anxiety and depression appear to coexist in the majority of depressed patients in both developing and developed countries.[86,87,88 and 89] Indeed, many mental health professionals now support the grouping of depression, anxiety, and other conditions often found to coexist in a single category—referred to as common mental disorders (CMD).[ 90,91,92 and 93] This chapter at times includes research that has examined CMD because it not only provides data that would eitherwise be absent, but also offers an accurate reflection of the high frequency with which these coexisting mental disorders occur. In addition to anxiety, several other conditions frequently coexist with depression; these include panic and dissociative disorders, neurasthenia, and sleep problems. Recent studies rank CMD among the most important causes of morbidity in primary care settings. For example, a review of the recent literature on CMD from South Asia  indicated that these disorders can be detected in more than a third of people who seek primary health care. A World Health Organization (WHO) collaborative study provided important information on the form, frequency, and outcome of psychological disorders seen in general health care settings. This study was carried out in 14 countries in different parts of the world: Brazil, Chile, the Federal Republic of Germany, France, Greece, India, Italy, Japan, the Netherlands, Nigeria, the People's Republic of China, Turkey, the United Kingdom, and the United States. In the
OCR for page 292
Neurological, Psychiatric, and Developmental Disorders: Meeting the Challenge in the Developing World study, 25,916 people aged 18 to 65 who consulted health care services were screened. Well-defined psychological problems were found in 24 percent of these subjects; most common were depressive disorders, anxiety disorders, alcohol use disorders, somatoform disorders, and neurasthenia. The results of the WHO study indicate a strong association between CMD and disability, defined as impairment of physical and social functioning. Disability levels were found to be greater on average among primary care patients with a psychological disorder than among those with common chronic diseases such as hypertension, diabetes, arthritis, and back pain. This finding of enhanced disability for psychological disorders was consistent across centers, across time, and across individual diagnoses.[33,34,97,98] The conditions categorized as CMD were also found frequently to be chronic. Approximately half of those with CMD when they first sought primary care continued to be afflicted a year later. People with CMD frequently seek primary care for physical symptoms. The latter may either serve as a risk factor for mental illness or result from somatization of psychological symptoms. As a result, CMD contributes significantly to the workload in both primary health care clinics and specialty medical clinics (Table 9-5).[94,97,98]
OCR for page 293
Neurological, Psychiatric, and Developmental Disorders: Meeting the Challenge in the Developing World TABLE 9-3 Selected Prevalence Studies of Depression Country Population Method Prevalence per 1,000 Population at Risk Lesotho  Rural village (n = 356); age 19–93 Sample survey Modules of DIS 88.5 South Africa  Rural village (n = 481); age > 18 Two-stage sample survey SRQ and PSE 180 Uganda  Two rural villages (n = 206); age > 18 Homestead survey PSE/SPI 143 males 226 females Taiwan  Rural 6 Taiwan  Urban, small town 11 Taiwan  Taipei (urban) 8 Taiwan  Urban and rural (n = 11,004); age 18–65 DIS 8 South Korea  National sample (n = 5,100); adults 18–65 DIS 23 India  Rural (n = 4,481) Interviews by trained field worker 430 India  Urban (n = 4,481) Interviews by field worker 10 China  (n = 388,136) Neurotic depression, 0.37 affective psychosis, 13 neurasthenia Brazil  3 urban localities Household survey 13–67 across different localities Dubai  Females (n = 300) 137 Australia  Canberra (n = 756) Household survey PSE 26 male 67 female 48 total United Kingdom  Camberwell (n = 800) Household survey PSE 48 male 90 female 70 total Holland  Nijmegen (n = 3,232) Household survey PSE 55 Finland  (n = 742) Household survey PSE 46 United Kingdom  Camberwell Cypriot community in inner London (n = 307) Household survey PSE 42 male 71 female 56 total Italy  Sardinia (n = 374) Household survey PSE 52 male 110 female 83 total United States of America  48 contiguous states (n = 8098); age 15–54 Household survey 77 male 129 female annual prevalence United Kingdom  Sample of total population excluding Northern Ireland and the highlands and islands of Scotland (n = 10,1108); age 18–64 Household survey CIS-R and SCAN 18 male 27 female one week prevalence
OCR for page 328
Neurological, Psychiatric, and Developmental Disorders: Meeting the Challenge in the Developing World 201. M. Cvjetkovic-Bosnjak, A. Knezevic, and B. Soldatovic-Stajic. Depression in older persons. Medicinski Pregled Mar-Apr;53(3–4)-184–186, 2000. 202. J.E. Wells, J.A. Bushell, A.R. Hornblow, P.R. Joyce, and M.A. Oakley-Browne. Christchurch psychiatric epidemiology study part 1: Methodology and lifetime prevalence for specific psychiatric disorders. Australian and New Zealand Journal of Psychiatry 23, 315–326, 1989. 203. H.U. Wittchen, S. Zhao, R.C. Kessler, and W.W. Eaton. DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. Archives of General Psychiatry May;51(5):355–364, 1994. 204. M. Eddleston, M.H. Rezvi Sheriff, and K. Hawton. Deliberate Self-Harm in Sri Lanka: An overlooked tragedy in the developing world. British Medical Journal 137:133–135, 1998. 205. J.A. Bartlett, A. Andreoli, T. Pascual, and S.E. Keller. Recent benzodiazepine use in depressed patients: A confound of psychoimmunologic studies? Brain, Behavior and Immunity Dec;10(4):380–386, 1996. 206. A.F. Jorm. Does old age reduce the risk of anxiety and depression? A review of epidemiological studies across the adult life span. Psychological Medicine 30, 11–22, 2000. 207. E. Cemerinski, R.G. Robinson, and J.T. Kosier. Improved recovery in activities of daily living associated with remission of poststroke depression. Stroke Jan;32(1):113–117, 2001. 208. H. Brodaty. Think of depression—Atypical presentations in the elderly. Australian Family Physician Jul 22(7)1195–1203, 1993. 209. J. Scott, D. Eccleston, and R. Boys. Can we predict the persistence of depression? British Journal of Psychiatry Nov;161:633–637, 1992. 210. M.M Weissman, S. Wolk, R.B. Goldstein, D. Moreau, P. Adams, S. Greenwald, et al. Depressed Adolescents Grown Up. Journal of the American Medical Association May 12;281(18):1707–1713, 1999. 211. M.M. Weissman, S. Wolk, P. Wickramaratne, R.B. Goldstein, P. Adams, S. Greenwald, et al. Children with Prepubertal-Onset Major Depresive disorder and Anxiety Grown up. Archives of General Psychiatry Sep;56:794–801, 1999. 212. M.B. Keller, P.W. Lavori, T.I. Mueller, J. Endicott, W. Coryell, R.M. Hirschfeld, et al. Time to recovery, chronicity, and levels of psychopathology in major depression. A 5-year prospective follow-up of 431 subjects. Archives General Psychiatry Oct;49(10):809–816, 1992. 213. M. Piccinelli and G. Wilkinson. Outcome of depression in psychiatric settings. British Journal of Psychiatry March 164(3)297–304, 1994. 214. J. Scott, W.A. Barker, and D. Eccleston. The Newcastle Chronic Depression Study. Patient characteristics and factors associated with chronicity. British Journal of Psychiatry Jan;152:28–33, 1988. 215. G.B. Cassano, L. Musetti, G Perugi, A. Soriani, V. Mignani, D.M. McNair, et al. A proposed new approach to the clinical sub-classification of depressive illness. Pharmacopsychiatry Jan 21(1):19–23, 1988. 216. A. Marneros, A. Deister, and A. Rhode. Stability of diagnosis in affective, schizoaffective and schizophrenic disorders. Cross sectional versus longitudinal diagnosis. European Archives Psychiatry and Clinical Neurosciences 241(3):187–192, 1991.
OCR for page 329
Neurological, Psychiatric, and Developmental Disorders: Meeting the Challenge in the Developing World 217. J. Angst and M. Preisig. Outcome of a clinical cohort of unipolar, bipolar and schizoaffective patients. Results of a prospective study from 1959–1985. Archives of Neurological Psychiatry 146(1):17–23, 1995. 218. R.S. Murthy, K. Kuruvilla, A. Verghese, and B.M. Pulimood. Psychiatric illness at general hospital medical clinic. Journal of the Indian Medical Association. Jan 1;66(1):6–8, 1976. 219. C. Shamsundar, R.L. Kapur, U.K. Sundaram, S. Pai, and G.N. Nagarathna. Involvement of the GPs in urban mental health care. Journal of the Indian Medical Association, 72:310–313, 1978. 220. S. Gautam, R.L. Kapur, and C. Shamasundar. Psychiatric morbidity and referral in General practice. Indian Journal of Psychiatry 22:295–297, 1980. 221. M.I. Isaac, R.L. Kapur, C.R. Chandrasekhar, M. Kapur, and R. Parthasarathy. Mental health delivery in rural primary health care—Development and evaluation of a pilot training programme. Indian Journal of Psychiatry 24:131–132, 1982. 222. C. Shamsundar, U.K. Sundaram, S. Kalyanasundaram, S. Pai, and R.L. Kapur. Training of GPs in mental health—Two year experience. Indian Journal of Psychological Medicine, 3:85–89, 1980. 223. C. Shamsundar, R.L. Kapur, M.K. Isaac, and U.K. Sundaram. Orientation course in psychiatry for GPs. Indian Journal of Psychiatry 25:298, 1983. 224. N.N. Wig and R.S. Murthy. Manual of mental health for primary care physicians. Indian Council of Medical Research: New Delhi, 1981. 225. M.K. Isaac, C.R. Chandrasekhar, and R.S. Murthy. Mental Health care by primary care doctors. National Institute of Mental Health and NeuroSciences: Bangalore, 1994. 226. T.G. Sriram, K. Kishore, S. Moily, C.R. Chandrashekar, M.K. Isaac, and R.S. Murthy. Minor psychiatric disturbances in primary health care: A study of their prevalence and characteristics using a simple case detection technique. Indian Journal of Psychiatry 3:212–226, 1987. 227. R.S. Murthy. Economics of mental health care in developing countries. In: International review of psychiatry, Lieh Mak, F. and Nadelson, C.C. eds. American Psychiatric Press: Washington, D.C.; 2:43–62, 1996. 228. A. Mohit. Mental health in the Eastern Mediterranean Region of the World Health Organization with a view of the future trends. East Mediterranean Health Journal Mar;5(2):231–240, 1999. 229. S. Davoid. Comprehensive report on integration of mental health into primary health care systems (in the Farsi language, limited circulation) Ministry of Health and Medical Education, Tehran, Iran, 1992. 230. N.N. Wig. WHO and mental health—A view from developing countries. Bulletin of the World Health Organization 78(4):502–503, 2000. 231. WHO/EMRO. Intercountry Meeting on development of mental health indicators, Alexandria, Dec, 1999. D. Shahmohammadi. Personal communication to Dr. Ahmad Mohit, Regional Advisor, Mental Health, WHO/EMRO, May 30, 2000. 232. D.G. Jacobs. National Depression Screening Day: Educating the public, reaching those in need of treatment, and broadening professional understanding Harvard Review of Psychiatry Sept.–Oct. 3(3):156–159, 1995. 233. R.G. Priest, R. Gimbrett, M. Roberts, and J. Steinhart. Reversible and selective inhibitors of monoamine oxidase A in mental and other disorders. Acta Psychiatrica Scandinavica 386:40–43, 1995.
OCR for page 330
Neurological, Psychiatric, and Developmental Disorders: Meeting the Challenge in the Developing World 234. R.G. Priest, E.S. Paykel, and D. Hart. Progress in defeating depression. Psychiatric Bulletin, 19:491–495, 1995. 235. N. Rettersol. National Plan for Suicide Prevention in Norway. Italian Journal of Suicidology. 5:19–24, 1995. 236. E.S. Paykel, D. Hart, and R.G. Priest. Changes in public attitudes to depression during the defeat depression campaign. British Journal of Psychiatry Dec 173:519–522, 1998. 237. V. Patel and R. Thara. Preventive programmes in low income countries. Sage: New Delhi, 2000. 238. V. Eapen, L.I. al-Gazali, S. Bin-Othman, M.T. Abou-Saleh, K.A. el-Nasser, R. Ramzy, et al. School Mental Health Screening: A Model for Developing Countries. Journal of Tropical Pediatrics Feb;45:53–55, 1999. 239. M. Mubbashar. School mental health program in Pakistan. In: Preventing Mental Illness—Mental Health Promotion in Primary Care. Jenkins, R. and Ustun, T.B., eds. Wiley: Chicester, 1998. 240. A. Rahman, M.H. Mubbashar, R. Gater, and D. Goldberg. Randomized trial of impact of school mental health program in rural Rawalpindi, Pakistan. Lancet 352:1022–1025, 1998. 241. M. Olfson, J. Gorman, and H. Pardes. Investing in mental health research. Journal of Nervous and Mental Disease 183, 421–424, 1995. 242. S. J. Taylor, D. Kingdon, and R. Jenkins. How are nations trying to prevent suicide? An analysis of national suicide prevention strategies. Acta Psychiatrica Scandinavica 95:457–463, 1996. 243. W. Rutz, L. Von Knorring, and J. Walinder. Frequency of suicide on Gotland after systematic post-graduate education of general practitioners. Acta Psychiatrica Scandinavica. 80:151–154, 1989. 244. K. Michel, C. Frey, K. Wyss, and L. Valach. An exercise in improving suicide reporting in print media. Crisis 21(2):71–79, 2000. 245. B. Ahrens, M. Linden, H. Zaske, and H. Berzewski. Suicidal behavior—Symptom or disorder? Comprehensive Psychiatry Mar–Apr;41(2 Supplement1):116–121, 2000. 246. A. Varnik. Suicide in the former republics of the USSR. Psychiatric Fennica 29:150–162, 1998. 247. Department of Health. Safer Services: National Confidential Inquiry into Suicide and Homicide by People with Mental Illness. (Appleby, L., Director). Department of Health: London, 1999. 248. M. Upanne. A model for the description and interpretation of suicide prevention Suicide Life Threatening Behavior 29(3):241–255, Autumn 1999. 249. L. Maruilli-Koenig, ed. National Strategies for the Prevention of Suicide. Information Support Unit of the United Nations Department for Policy Coordination and Sustainable Development. Kiosk Online Oct./Nov. 2(5), 1996. 250. R. Joffe, S. Sokolov, D. Streiner. Anti-depressant treatment of depression: A metaanalysis. Canadian Journal of Psychiatry Dec 41(10):613–616, 1996. 251. C. Brown and H.C. Schulberg. The efficacy of psychosocial treatments in primary care: A review of randomized clinical trials. General Hospital Psychiatry Nov 17(6): 414–424, 1995.
OCR for page 331
Neurological, Psychiatric, and Developmental Disorders: Meeting the Challenge in the Developing World 252. M. Abas, J.C. Broadhead, P. Mbape, and G. Khumalo-Sakatukwa. Defeating depression in the developing world: A Zimbabwean model. British Journal of Psychiatry Mar;164(3):293–296, 1994. 253. M. Hollifield, W. Katon, and N. Morojele. Anxiety and depression in an outpatient clinic in Lesotho, Africa International Journal of Psychiatric Medicine 24(2):179–188, 1994. 254. O.A. Abiodun. A study of mental morbidity among primary care patients in Nigeria Comprehensive Psychiatry 34:10–13, 1993. 255. C. Wright, M.K. Nepal, and W.D.A. Bruce-Jones. Mental health patients in primary care services in Nepal. Asia-Pacific Journal of Public Health 3:224–230, 1989. 256. M. Joukamaa, V. Lehtinen, and H. Karlsson. The ability of general practitioners to detect mental disorders in primary health care. Acta Psychiatrica Scandinavica 91:52–56, 1995. 257. P.P. Sales. Primary mental health care in Nicaragua five years later. Social Science Medicine 37:1585–1586, 1993. 258. W. Katon. Will improving detection of depression in primary care lead to improved depressive outcomes? General Hospital Psychiatry 17:1–2, 1995. 259. A. Kigamwa. Psychiatry morbidity and referral rate among medical in-patients at the Kenyatta National Hospital. East African Medical Journal May;68(5):383–388, 1991. 260. G. Simon. Long term prognosis of depression in primary care. Bulletin of the World Health Organization 78(4):439–445, 2000. 261. W. Katon, M. Von Korff, E. Lin, T. Bush, and J. Ormel. Adequacy and duration of antidepressant treatment in primary care Medical Care 30:67–76, 1992. 262. O. Spigset. Adverse reactions of selective serotonin reuptake inhibitors: Report from a spontaneous reporting system. Drug Safety March 20(3):277–287, 1999. 263. G. Isacsson, G. Boethius, S. Henriksson, J.K. Jones, and U. Bergman. Selective serotonin reuptake inhibitors have broadened the utilzation of antidepressant treatment in accordance with recommendations. Finding from a Swedish prescription database. Journal of Affective Disorders Apr;53(1):15–22, 1999. 264. E. Frank, D.J. Kupfer, J. M. Perel, C. Cornes, D.B. Jarrett, A.G. Mallinger, et al. Three-year outcomes for maintenance therapies in recurrent depression Archives of General Psychiatry Dec;47(12); 1093–1099, 1990. 265. P. Liu. Clinical psychopharmacology in China: The last decade. Psychiatry Clinical Neurosciences Dec;52 Supplement:S190–192, 1998. 266. I.M. Anderson. Selective sertonin reuptake inhibitors versus trycyclic antidepressants: A meta-analysis of efficacy and tolerability. Journal of Affective Disorders 58:19–36, 2000. 267. C.M. Pare. The present status of monoamine oxidase inhibitors. British Journal of Psychiatry Jun;146:576–584, 1985. 268. F. Quitkin, J.W. Stewart, P.J. McGrath, E. Tricamo, J.G. Rabkin, K. OcepekWelikson, E. Nunes. W. Harrison, and D.F. Klein. Columbia atypical depression. A subgroup of depressives with better response to MAOI than to tricyclic anti-depressants or placebo. British Journal of Psychology Sep 21:30–34, 1993. 269. M.H. Lader. The Efficacy of antidepressant medication In: The Management of Depression, Checkley, S., ed. Blackwell: London, pp.188–211, 1998. 270. G. Singh and R. Sharma. Anxiety and Depressive Neurosis: Their response to anxiolytic and antidepressant treatment. Indian Journal of Psychiatry 29:49–56, 1987.
OCR for page 332
Neurological, Psychiatric, and Developmental Disorders: Meeting the Challenge in the Developing World 271. F. Song, N. Freemantle, T.A. Sheldon, A. House, P. Watson, A. Long, et al. Selective serotonin reuptake inhibitors: Meta-analysis of efficacy and acceptability. British Medical Journal Mar 13;306(6879):683–687, 1993. 272. E. Trindade and D. Menon. Selective serotonin reuptake inhibitors (SSRIs) for major depression Part 1: Evaluation of the clinical literature. Canadian Coordinating Office for Health Technology Assessment (Report 3E): Ottawa, 1997. 273. R.J. Boerner and H.J. Moller. The importance of new antidepressants in the treatment of anxiety/depressive disorders. Pharmacopsychiatry Jul;32(4):119–126, 1999. 274. J.P. Lepine, J. Goger, C. Blashko, C. Probst, M.F. Moles, J. Kosolowski, et al. A double-blinded study of the efficacy and safety of sertraline and clomipramine in outpatients with severe major depression. International Clinical Psychopharmacology Sep;15(5):263–271, 2000. 275. S.M. Razali and C.T. Hasanah. Cost-effectiveness of cyclic antidepressants in developing countries Australian New Zealand Journal of Psychiatry Apr;33:283–284, 1999. 276. M. Hotopf, G. Levis, and C. Normand. Are SSRIs a cost-effective alternative to tricyclic? British Journal of Psychiatry 168:404–409, 1996. 277. P.G. Janicak, J.M.Davis, S.H. Preskorn and F.J. Ayd. Principles and Practice of Psychopharmacotherapy, 2nd edition. Williams & Wilkins: Baltimore, MD, 1997. 278. G.L. Birbeck. Barriers to care for patients with neurologic disease in rural Zambia Archives of Neurology March 57(3):414–417, 2000. 279. J.F. Gumnick and C.B. Nemeroff. Problems with currently available antidepressants. Journal of Clinical Psychiatry 10(Supplement 61):5–15, 2000. 280. M. Fava. New approaches to the treatment of refractory depression. Journal of Clinical Psychiatry 61(1):26–32, 2000. 281. A.I. Scott. Contemporary practice of electroconvulsive therapy. British Journal of Hospital Medicine Apr 6–19;51(7):334–338, 1994. 282. H. Folkerts. Electroconvulsive therapy of depressive disorders. Therapeutische Umschau Feb;57(2):90–94, 2000. 283. A.I. Scott. Does ECT alter brain structure? American Journal of Psychiatry Sep;152(9):1403, 1995. 284. Royal College of Psychiatrists. The ECT Handbook. Royal College of Psychiatrists: London, 1995 (Council report CR39) 285. A.S. Hale. ABC of mental health: Depression. British Medical Journal 315:43-46, 1997. 286. G. Goodwin. Mood Disorder. In: Companion to Psychiatric Studies, 6th Edition. Johnstone, E., Freeman, C.P.L., and Zealby, A.K., eds. Churchill Livingstone: Kent, U.K., 1998. 287. R. Desjarlais, L. Eisenberg, B. Good, and A. Kleinman. World Mental Health. Problems and Priorities in Low-income Countries. Oxford University Press: New York, 1995. 288. O.A. Abiodun. The role of psychosocial factors in the causation, course and outcome of physical disorders: A review. Eastern African Medical Journal Jan;71(1):55–59, 1994. 289. A.E. Zretsky, Z.V. Segal, and M. Gemar. Cognitive therapy for bipolar depression: A pilot study. Canadian Journal of Psychiatry Jun;44(5):491–494, 1999.
OCR for page 333
Neurological, Psychiatric, and Developmental Disorders: Meeting the Challenge in the Developing World 290. I.D. Glick, T. Suppes, C. DeBattista, R.J. Hu, and S. Marder. Psychopharmacologic treatment strategies for depression, bipolar disorder, and schizophrenia. Annals of Internal Medicine Jan2;134(1):47–60, 2001. 291. D.L. Evans, J. Staab, H. Ward, J. Leserman, D.O. Perkins, R.N. Golden, J.M. Petitto. Depression in the medically ill: Management considerations. Depression and Anxiety 4(4):199–208, 1996–1997. 292. S.W. Perry and J. Markowitz. Psychiatric interventions for AIDS-spectrum disorders. Hospital Community Psychiatry Oct;37(10):1001–1006, 1986. 293. A. Bergant, T. Nguyen, R. Moser, and H. Ulmer. Prevalence of depressive disorders in early puerperium. Gynakol Geburtshilfliche Rundsch 38(4):232–237, 1998. 294. D.S. Gruen. A group psychotherapy approach to postpartum depression. International Journal of Group Psychotherapy Apr;43(2):191–203, 1993. 295. A.T. Beck, M.Kovacs, and A. Weissman. Assessment of suicidal intention: The scale for suicide ideation. Journal of Consulting Clinical Psychiatry April 47(2):343–352, 1979. 296. P.C. Kendall and S.M. Panichelli-Mindel. Cognitive-behavorial treatments. Journal of Abnormal Child Psychology Feb 23(1):107–124, 1995. 297. L. Mynors-Wallis, I. Davies, A. Gray, F. Barour, and D. Gath. A randomized controlled trial and cost analysis of problem-solving treatment for emotional disorders given by community nurses in primary care. British Journal of Psychiatry Feb;170:113–119, 1997. 298. J.E. Barrett, J.W. Williams Jr., T.E. Oxman, W. Katon, E. Frank, M.T. Hegel et al. The treatment effectiveness project. A comparison of the effectiveness of paroxetine, problem-solving therapy, and placebo in the treatment of minor depression and dysthymia in primary care patients: Background and research plan. General Hospital Psychiatry Jul-Aug;21(4):260–273, 1999. 299. C. Dorwick, G. Dunn, J.L. Ayuso-Mateos, O.S. Dalgard, H. Page, V. Lehtinen, et al. Problem solving treatment and group psychoeducation for depression: Multicentre randomized controlled trial. Outcomes of Depression International Network (ODIN) Group. British Medical Journal Dec 9;321 (7274):1450–1454, 2000. 300. D.J. Miklowitz and M.J. Goldstein. Behavorial family treatment for patients with Bipolar affective disorder Behavior Modification Oct 14(4):457–489, 1990. 301. T. Kendrick. Primary care options to prevent mental illness. Annals of Medicine Dec;31(6):359–363, 1999. 302. N. Nalini, V. Kumaraiah, and D. Subbakrishna. Cognitive behaviour therapy in the treatment of neurotic depression National Institute of Mental Health and Neurosciences 14, 31–35, 1996. 303. A. Sumathipale, R. Hanwella, S. Hwege and A. Mann. Randomised controlled trial of cognitive behaviour therapy for respected consultations for medically unexplained symptoms: A feasibility study in Sri Lanka. Psychological Medicine 30:749–758, 2000. 304. D. Dudek and A. Zieba. Development and application of cognitive therapy in affective disorders [Article in Polish] Psychiatrica Polska 34(1):81–88, 2000. 305. S.X. Li and M.R. Phillips. Witch doctors and mental illness in mainland China: A preliminary study. American Journal of Psychiatry Feb;147(2):221–224, 1990. 306. A.P. Reeler. Pathways to psychiatric care in Harare, Zimbabwe. The Central African Journal of Medicine 38(1): 1–7, 1992
OCR for page 334
Neurological, Psychiatric, and Developmental Disorders: Meeting the Challenge in the Developing World 307. S. Bondestam, J. Garssen, and A.I. Abdulwakil. Prevalence and treatment of mental disorders and epilepsy in Zanzibar Acta Psychiatrica Scandinavica Apr;81(4):327–331, 1990. 308. O. Gureje, R.A. Acha, and O.A. Odejide. Pathways to psychiatric care in Ibadin, Nigeria. Tropical and Geographical Medicine 47(3):125–129, 1995. 309. B. Bloch. Treatment of psychiatric patients in Tanzania. Acta Psychiatrica Scandinavica 364(83):122–126, 1991. 310. S.W. Acuda. Mental health problems in Kenya today: A review of research. East African Medical Journal Jan 60(1):11–14, 1983. 311. F. Schulsinger and A. Jablensky. The national mental health programme in the United Republic of Tanzania: A report from WHO and DANIDA. Acta Psychiatrica Scandinavica 83(364):1–132, 1991. 312. K.H. Heggenhougen and L. Gilson. Perceptions of efficacy and the use of traditional medicine, with examples from Tanzania. Curare 20:5–13, 1997. 313. S.F. Kaaya and M.T. Leshabari. Depressive illness and primary health care in sub-Saharan Africa: With special reference to Tanzania. Central African Journal of Medicine, 1999. 314. T.B. Ustun. The global burden of mental disorders. American Journal of Public Health Sep:89(9):1315–1318, 1999. 315. W. Gulbinat, R. Manderscheid, A. Beigel, and J.A. Costa e Silva. A multinational strategy on mental health policy and care. A WHO collaborative initiative and consultative program. In: Handbook of Mental Health Economics and Health Policy. Schizophrenia Mosacarelli, M., Rupp, A., and Sartorius, N., eds. John Wiley & Sons: Chicester, 1996. 316. R.S. Murthy. Economics of mental health care in developing countries. In: International Review of Psychiatry. Lieh Mak, F. and Nadelson, C.C., eds. American Psychiatric Press: Washington, D.C., 2:43–62, 1996. 317. D. Chisholm. Challenges for the international application of mental health economics Epidemiology and Psychiatric Sociology. Jan–March 8(1):11–15, 1999. 318. A. Shah and R. Jenkins. Mental health economic studies from developing countries reviewed in the context of those from developed countries. Acta Psychiatrica Scandinavica 100:1–18, 1999. 319. I. Blue and T. Harpham. The World Bank World Development Report 1993: Investing in Health Reveals the burden of common mental disorders, but ignores its implications British Journal of Psychiatry July 165(2):9–12, 1994. 320. R.S. Murthy. Conversion factor instability in international comparisons of health care expenditure: Some econometric comments. Journal of Health Economics Aug;11(2):183–187, 1992. 321. P. Cowley and J.R. Wyatt. Schizophrenia and manic-depressive illness. In: Disease control priorities in developing countries. Jamison, D.T., Mosley, W.H., Measham, A.R., and Bobadilla, J.L., eds. Oxford University Press: Oxford, pp.661–670, 1993. 322. W. Xiong, M.R. Phillips, R. Wang, Q. Dai, J. Kleinman, and A. Kleinman. Family-based intervention for schizophrenic patients in China: A randomised controlled trial. British Journal of Psychiatry 165:239–247, 1995. 323. Q. Wang, Y.Gong, K. Niu. Q. Wang., Y. Gong, and K. Niu. The Yantai model of community care for rural psychiatric patients British Journal of Psychiatry 1994;165(Suppl24):107–113
OCR for page 335
Neurological, Psychiatric, and Developmental Disorders: Meeting the Challenge in the Developing World 324. M.K. Isaac and R.L. Kapur. A cost-effective analysis of three different methods of psychiatric case finding in the general population. British Journal of Psychiatry 137:540–546, 1980. 325. L.S. Gillis, A. Koch, and M. Joyi. The value and cost-effectiveness of a home-visiting programme for psychiatric patients. South African Medical Journal 77:309–310, 1989. 326. M. Knapp, J. Beecham, A. Fenyo, and A. Hallam. Community mental health care for former hospital in-patients. Predicting costs from needs and diagnoses. British Journal of Psychiatry 27:10–18, April 1995. 327. W. Hargreaves, M. Shumway, T. Hu, and B. Cuffel. Cost Outcome Methods for Mental Health. Academic Press: London, 1997. 328. A. Creese. Global trends in health care reform. World Health Forum 15(4):317–322, 1994. 329. L. Kumaranayake and C. Watts. Cost-effectiveness estimates of the Mwanza sexually transmitted diseases intervention. Lancet Mar 28;351(99107):989–990, 1998. 330. D. Chisholm, K. Sekar, K. Kishore Kumar, K. Saeed, S. James, M. Mubbahar, et al. Integration of mental health care into primary care: Demonstration cost-outcome study in India and Pakistan. British Journal of Psychiatry 176:581–588, 2000. 331. R. Sturm and K. Wells. Health insurance may be improving-but not for individuals with mental illness. Health Services Research April:35(l pt 2):253–262, 2000. 332. D.J. Katzelnick, K.A. Kobak, J.H. Greist, J.W. Jefferson, and H.J. Henk. Effect of primary care treatment of depression on service use by patients with high medical expenditures. Psychiatric Services 48(10):59–64, Jan 1997. 333. D. Goldberg, G. Jackson, R. Gater, M. Campbell, and N. Jennett. The treatment of common mental disorders by a community team based in primary care: A cost-effectiveness study. Psychological Medicine May;26(3):487–492, 1996. 334. L.V. Rubenstein, M. Jackson-Triche, J. Unutzer, J. Miranda, K. Minnium, M.L. Pearson, et al. Evidence-based care for depression in managed primary care practices Health Affirmation Sep–Oct;18(5):89–105, 1999. 335. J.R. Lave, R.G. Frank, H.C. Schulber, and M.S. Kamlet. Cost-effectiveness of treatments for major depression in primary care practice. Archives of General Psychiatry July;55(7):645–651, 1998. 336. W. Katon. Treatment trials in real world settings. Methodological issues and measurement of disability and costs. General Hospital of Psychiatry Jul–Aug.:21(4):237–238, 1999. 337. R.C. Kessler, C. Barber, H.G. Birnbaum, R.G. Frank, P.E. Greenberg, R.M. Rose, G.E. Simon, and P. Wang. Depression in the workplace: effects on short-term disability. Health Affairs (Millwood) 18(5):163–171, Sep–Oct 1999. 338. K.B. Wells and C.D. Sherbourne. Functioning and utility for the current health of patients with depression or chronic medical conditions in managed, primary care practices Archives of General Psychiatry Oct;56(10):897–904, 1999. 339. R. Frank, J. Glazer, and T. McGurie. Measuring Distortion from Adverse Selection in Managed Health Care Boston University: Boston, 1999. 340. G.P. Kilonzo and N. Simmons. Development of mental health services in Tanzania: A reappraisal for the future. Social Science and Medicine 47(4):419–428, Aug 1998. 341. R Alarcon and S. Aguilar-Gaxiola. Mental health policy developments in Latin America. Bulletin of the World Health Organization 78:483–490, 2000.
OCR for page 336
Neurological, Psychiatric, and Developmental Disorders: Meeting the Challenge in the Developing World 342. O. Gureje and A. Alem. Mental health policy development in Africa. Bulletin of the World Health Organization 78:475–482, 2000. 343. M. Shepherd. Mental health as an integrant of primary medical care. Journal of the Royal College of General Practitioners 30:657–664, 1980. 344. B.J. Burns, D.A. Regier, and A.M. Jacobson. Factors relating to the use of mental health services in a neighborhood health center. Public Health Report 93(3):232–239, May-Jun 1978. 345. R. Jenkins. Developments in the primary care of mental illness—A forward look. International Review of Psychiatry 4:237–242, 1992. 346. J. Scott, T. Jennings, S. Standart, R. Ward, and D. Goldberg. The impact of training in problem-based interviewing on the detection and management of pyschological problems presenting in primary care British Journal of General Practice Jun;49:441–445, 1999. 347. M. Fulop. Residency training. Annals of Internal Medicine Jun;106(6):915, 1987. 348. S. Morley and S.B. Barton. Specificity of reference patterns in depressive thinking: Agency and object for self-representation. Journal of Abnormal Psychology Nov;108(4):655–66, 1999. 349. A.H. Mann, R. Blizard, J. Murray, J.A. Smith, N. Botega, E. MacDonald, et al. An evaluation of practice nurses working with general practitioners to treat people with depression. British Journal of General Practice 48:875–879, 1998. 350. O.A. Abiodun. Knowledge and attitude concerning mental health of primary health care workers in Nigeria. International Journal of Social Psychiatry 37(2):113–120, Summer 1991. 351. C.A. Orchard and R. Karmaliani. Community development specialists in nursing for developing countries Image Journal of Nursing School 31 (3):295–299, 1999. 352. G.E. Simon, E.H.B. Lin, W. Katon, K. Saunders, M. Von Korff, E. Walker, et al. Outcomes of “inadequate” antidepressant treatment. Journal of General Internal Medicine 10:663–670, 1995. 353. E.H.B. Lin and W.J. Katon. Beyond the diagnosis of depression. General Hospital Psychiatry 20:207–208, 1998.
OCR for page 337
Neurological, Psychiatric, and Developmental Disorders: Meeting the Challenge in the Developing World This page in the original is blank.
OCR for page 338
Neurological, Psychiatric, and Developmental Disorders: Meeting the Challenge in the Developing World Summary of Findings: Stroke in Developing Countries Stroke ranked as the third leading cause of death in 1990 in developing countries and was responsible for about 2.4 percent of disability-adjusted life years (DALYs) worldwide. Projections for 2020 place stroke fifth among the causes of disease burden for developing countries. Prevalence and incidence rates for stroke vary dramatically among populations and may be influenced by economic, behavioral, and genetic factors, among others. Comparative epidemiological studies of stroke based on common definitions, methods, and modes of data presentation are needed to increase understanding of this disease. Because of the high risk for death, long-term disability, and recurrence after a first stroke, prevention is key to reducing the public health impacts of cerebrovascular disease. And prevention is feasible, given the remarkable reduction in stroke mortality achieved in several developed countries. Low-cost community health education programs that promote exercise, healthy diets, and smoking cessation may significantly reduce risk of stroke in developing countries. Several low-cost treatments for hypertension, diabetes, and other conditions are likely to reduce significantly the incidence and severity of stroke and stroke-related vascular disease in developing countries. Primary health care workers, nurses, and physicians play an important role in detecting, diagnosing, and treating hypertension and other conditions that increase stroke risk, and in ensuring compliance with treatment. Key resources such as stroke units in major hospitals, rehabilitation facilities, and post-stroke community support programs may serve a minority of patients, but promote the development and introduction of appropriate, cost-effective methods and technology for stroke prevention, treatment, and rehabilitation.
Representative terms from entire chapter: